Search ROIV
Roivant Sciences Ltd.
Nasdaq · CIK 1635088
Last close35.72
Daily change+0.22 (0.62%)
10 Years gain+243.46%
Dividends TTM0
Dividend yield0.00%
Fundamental Analysis
ROIV · STANDARD
SIC 2834 · Pharmaceutical Preparations · Fiscal year end 0331
Fundamental
47.1Momentum
0.0Acceleration
0.0Confidence
90.0Annual Revenue6
Quarterly Revenue23
Annual CFO6
Balance SheetAvailable
RankingEligible
Score Breakdown
Growth5.9 / 25
Quality12.2 / 25
Capital Efficiency3.5 / 20
Balance Sheet15.0 / 15
Shareholder Economics8.1 / 10
Forward Indicators0.0 / 5
Signals
Share count reductionDiluted share count declined 0.2684%.
Warnings
Gross margin compression · MEDIUMGross margin compressed by 16344.036 percentage points.
Operating margin compression · MEDIUMOperating margin compressed by 31796.2301 percentage points.
Key Metrics
Revenue Growth TTM-78.05%OK
Revenue CAGR 3Y-36.01%OK
Gross Margin105.46%OK
Operating Margin-18,049.3%OK
FCF Marginn/aMISSING
FCF Growthn/aINSUFFICIENT_HISTORY
ROIC-473.94%OK
Incremental Operating Margin 3Yn/aNOT_MEANINGFUL
Net Debt / CFOn/aNOT_MEANINGFUL
Diluted Share Growth 1Y-0.27%OK
SBC / Revenuen/aMISSING
SBC / FCFn/aNOT_MEANINGFUL
Financial History
| Period | Revenue | Gross Profit | Operating Income | CFO | FCF | Gross Margin | Op Margin | FCF Margin | ROIC | Shares |
|---|---|---|---|---|---|---|---|---|---|---|
| 2025 FY Mar 31, 2026 | $8.26M | $778.50M | -$515.07M | -$750.35M | -$758.56M | 9,424.88% | -6,235.69% | -9,183.51% | -2,244.92% | 693.86M |
| 2025 FY Mar 31, 2025 | $29.05M | $139.44M | -$1.00B | -$839.45M | -$844.05M | 479.95% | -3,453.32% | -2,905.21% | n/a | 725.4M |
| 2025 FY Mar 31, 2024 | $32.71M | $5.38B | $4.50B | -$765.27M | -$766.65M | 16,449.49% | 13,746.93% | -2,343.56% | n/a | 831.05M |
| 2024 FY Mar 31, 2023 | $31.53M | $31.53M | -$906.76M | -$843.39M | -$856.08M | 100% | -2,875.87% | -2,715.14% | n/a | 712.79M |
| 2023 FY Mar 31, 2022 | $55.29M | $55.29M | -$1.35B | -$677.73M | -$695.17M | 100% | -2,444.82% | -1,257.4% | n/a | 669.75M |
Formula Trace
| Metric | Value | Formula | Status | Source |
|---|---|---|---|---|
| Revenue TTM | $7.18M | sum latest 4 fiscal quarters Revenue | OK | 0001635088-26-000090, 0001635088-25-000016 |
| Revenue Growth TTM | -78.05% | Revenue_TTM / Revenue_TTM_1Y_ago - 1 | OK | 0001635088-26-000090, 0001635088-25-000016 |
| Revenue CAGR 3Y | -36.01% | (Revenue_current / Revenue_3Y_ago)^(1/3) - 1 | OK | 0001635088-26-000061 |
| Revenue CAGR 5Y | -19.07% | (Revenue_current / Revenue_5Y_ago)^(1/5) - 1 | OK | 0001635088-26-000061 |
| Gross Profit CAGR 3Y | 191.19% | (GrossProfit_current / GrossProfit_3Y_ago)^(1/3) - 1 | OK | 0001635088-26-000061 |
| Operating Income Growth | -128.83% | OperatingIncome_current / OperatingIncome_prior_year - 1 | OK | 0001635088-26-000090, 0001635088-25-000016 |
| FCF Growth | n/a | FCF_current / FCF_prior_year - 1 | INSUFFICIENT_HISTORY | derived |
| Revenue Growth Acceleration | n/a | 0.5*(Q0-Q1)+0.3*(Q1-Q2)+0.2*(Q2-Q3) | INSUFFICIENT_HISTORY | derived |
| Gross Profit Acceleration | n/a | 0.5*(Q0-Q1)+0.3*(Q1-Q2)+0.2*(Q2-Q3) | INSUFFICIENT_HISTORY | derived |
| Operating Income Acceleration | n/a | 0.5*(Q0-Q1)+0.3*(Q1-Q2)+0.2*(Q2-Q3) | INSUFFICIENT_HISTORY | derived |
| FCF Acceleration | n/a | 0.5*(Q0-Q1)+0.3*(Q1-Q2)+0.2*(Q2-Q3) | INSUFFICIENT_HISTORY | derived |
| Gross Margin | 105.46% | Gross Profit / Revenue | OK | 0001635088-26-000090, 0001635088-25-000016 |
| Operating Margin | -18,049.3% | Operating Income / Revenue | OK | 0001635088-26-000090, 0001635088-25-000016 |
| ROIC | -473.94% | NOPAT / Average Invested Capital | OK | 0001635088-26-000090, 0001635088-25-000016 |
| Net Debt / CFO | n/a | Net Debt / CFO | NOT_MEANINGFUL | 0001635088-26-000090 |
| Current Ratio | 16.72x | Current Assets / Current Liabilities | OK | derived |
| Revenue per Diluted Share | $0.01 | Revenue / Diluted Shares | OK | 0001635088-26-000090, 0001635088-25-000016 |
| SBC / FCF | n/a | SBC / FCF | NOT_MEANINGFUL | derived |